Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Exogenous E2F expression is growth inhibitory before, during, and after cellular transformation

Abstract

To gain insight into the tumor suppressor properties of E2F1, we investigated growth inhibition by the E2F family of transcription factors using a tissue culture model system. We first show that exogenous E2F expression causes an 80% decrease in NIH3T3 colony formation and activated c-Ha-Ras-mediated focus formation. Inhibition of Ras-mediated transformation was dependent upon E2F DNA binding activity but did not require amino- or carboxy-terminal E2F1 protein interaction domains. Because E2F upregulation has been suggested to be associated with a neoplastic phenotype, it was possible that increased E2F activity would not be inhibitory to previously transformed cells. However, we found that exogenous E2F was also inhibitory to growth of NIH3T3 cells previously transformed by Ras or Neu. Further characterization revealed that exogenous E2F expression is inhibitory at very early times after transfection, causing dramatic losses in transfected cell populations. Interestingly, those few cells which do establish appear to be unaffected by the overexpressed E2F. Therefore, we propose that increased E2F activity may only be tolerated in a subset of cells which have acquired specific alterations that are dominant over E2F-mediated growth inhibition.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Bargmann CI, Hung M-C and Weinberg RA . 1986 Cell 45: 649–657

  • Beijersbergen RL, Kerkhoven RM, Zhu L, Carlée L, Voorhoeve PM and Bernards R . 1994 Genes Dev 8: 2680–2690

  • Brideau AD, Banfield BW and Enquist LW . 1998 J Virol 72: 4560–4570

  • Chen C and Okayama H . 1987 Mol Cell Biol 7: 2745–2752

  • Cress WD, Johnson DG and Nevins JR . 1993 Mol Cell Biol 13: 6314–6325

  • Dignam JD, Lebovitz RM and Roeder RG . 1983 Nucleic Acids Res 11: 1475–1489

  • Dimri GP, Hara E and Campisi J . 1994 J Biol Chem 269: 16180–16186

  • Ferreira R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A and Trouche D . 1998 Proc Natl Acad Sci USA 95: 10493–10498

  • Field SJ, Tsai F-Y, Kuo F, Zubiaga AM, Kaelin Jr WG, Livingston DM, Orkin SH and Greenberg ME . 1996 Cell 85: 549–561

  • Finlay C, Hinds P and Levine A . 1989 Cell 57: 1083–1093

  • Flores AM, Kassatly RF and Cress WD . 1998 Oncogene 16: 1289–1298

  • Gumerlock PH, Meyers FJ, Kokoris SP, Wong G, McCormick FP and de Vere White RW . 1989 Anal Biochem 180: 158–168

  • Hammerschmidt W, Sugden B and Baichwal VR . 1989 J Virol 63: 2469–2475

  • Helin K, Harlow E and Fattaey A . 1993a Mol Cell Biol 13: 6501–6508

  • Helin K, Wu C-L, Fattaey AR, Lees JA, Dynlacht BD, Ngwu C and Harlow E . 1993b Genes Dev 7: 1850–1861

  • Hsieh J-K, Fredersdorf S, Kouzarides T, Martin K and Lu X . 1997 Genes Dev 11: 1840–1852

  • Huang H-JS, Yee J-K, Shew J-Y, Chen P-L, Bookstein R, Friedmann T, Lee EY-HP and Lee W-H . 1988 Science 242: 1563–1566

  • Ivey-Hoyle M, Conroy R, Huber HE, Goodhart PJ, Oliff A and Heimbrook DC . 1993 Mol Cell Biol 13: 7802–7812

  • Johnson DG, Cress WD, Jakoi L and Nevins JR . 1994 Proc Natl Acad Sci USA 91: 12823–12827

  • Kalejta RF, Brideau AD, Banfield BW and Beavis AJ . 1999 J Exp Cell Res 248: 322–328

  • Karlsreder J, Rotheneder H and Wintersberger E . 1996 Mol Cell Biol 16: 1659–1667

  • Kitagawa M, Higashi H, Suzuki-Takahashi I, Segawa K, Hanks SK, Taya Y, Nishimura S and Okuyama A . 1995 Oncogene 10: 229–236

  • Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin WGJ and Livingston DM . 1994 Cell 78: 161–172

  • Krek W, Xu G and Livingston DM . 1995 Cell 83: 1149–1158

  • Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, Dyson N and Helin K . 1993 Mol Cell Biol 13: 7813–7825

  • Lin SY, Black AR, Kostic D, Pajovic S, Hoover CN and Azizkhan JC . 1996 Mol Cell Biol 16: 1668–1675

  • Lindeman GJ, Gaubatz S, Livingston DM and Ginsberg D . 1997 Proc Natl Acad Sci USA 94: 5095–5100

  • Magae J, Wu C-L, Illenye S, Harlow E and Heintz NH . 1996 J Cell Sci 109: 1717–1726

  • Maniatis T, Fritsch EF and Sambrook J . 1982 Molecular cloning; a laboratory manual Cold Spring Harbor Laboratory Cold Spring Harbor, New York

    Google Scholar 

  • Marti A, Wirbelauer C, Scheffner M and Krek W . 1999 Nature Cell Biol 1: 14–19

  • Müller H, Moroni M, Vigo E, Peterson BO, Barteck JH and Helin K . 1997 Mol Cell Biol 17: 5508–5520

  • Phillips AC, Bates S, Ryan KM, Helin K and Vousden KH . 1997 Genes Dev 11: 1853–1863

  • Pierce AM, Fisher SM, Conti DJ and Johnson DG . 1998a Oncogene 16: 1267–1276

  • Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ and Johnson DG . 1998b Proc Natl Acad Sci USA 95: 8858–8863

  • Pierce AM, Schneider-Broussard S, Gimenez-Conti IB, Russell JL, Conti CJ and Johnson DG . 1999 Mol Cell Biol 19: 6408–6414

  • Roussel MF, Davis JN, Cleveland JL, Ghysdael J and Hiebert SW . 1994 Oncogene 9: 405–415

  • Saito M, Helin K, Valentine MB, Griffith BB, Willman CL, Harlow E and Look AT . 1995 Genomics 25: 130–138

  • Sellers WR, Rodgers JW and Kaelin Jr WG . 1995 Proc Natl Acad Sci USA 92: 11544–11548

  • Singh P, Wong SH and Hong W . 1994 EMBO J 13: 3329–3338

  • Verona R, Moberg K, Estes S, Starz M, Vernon JP and Lees JA . 1997 Mol Cell Biol 17: 7268–7282

  • Wang B, Kennan WS, Yasukawa-Barnes J, Lindstrom MJ and Gould MN . 1991a Cancer Res 51: 2642–2648

  • Wang B, Kennan WS, Yasukawa-Barnes J, Lindstrom MJ and Gould MN . 1991b Cancer Res 51: 5649–5654

  • Wells J, Held P, Illenye S and Heintz NH . 1996 Mol Cell Biol 16: 634–647

  • Wu CL, Zukerberg LR, Ngwu C, Harlow E and Lees JA . 1995 Mol Cell Biol 15: 2536–2546

  • Xu M, Sheppard KA, Peng CY, Yee AS and Piwnica-Worms H . 1994 Mol Cell Biol 14: 8420–8431

  • Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E and Dyson NJ . 1996 Cell 85: 537–548

  • Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D, Dyson N and Harlow E . 1993 Genes Dev 7: 1111–1125

Download references

Acknowledgements

We are grateful to Richard Burgess, Doug Cress, LW Enquist, Doron Ginsberg, Michael Gould, Ed Harlow, Kristen Helin, Wilhelm Krek, Jackie Lees, David Livingston, Joseph Nevins, Bill Sugden and Phillip Watson for providing plasmids and reagents and to Kathy Schell and Kristen Elmer for assistance with flow cytometry. We also thank members of the Farnham laboratory for critical readings of this manuscript. This work was supported in part by Public Health Service Grants CA07175, CA22484 and predoctoral training grants CA09135 and DAMD17-96-1-6109.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, T., Farnham, P. Exogenous E2F expression is growth inhibitory before, during, and after cellular transformation. Oncogene 19, 2257–2268 (2000). https://doi.org/10.1038/sj.onc.1203556

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203556

Keywords

Search

Quick links